The State of Psychedelic Therapy in 2026
Psychedelic therapy has moved from the fringes of psychiatry to front-page news, with clinical trials at major universities, FDA designations, and billions in investment. But the media narrative -- "psychedelics will revolutionize mental health treatment" -- often runs ahead of what the data actually shows. This article reviews the major clinical programs, what their results mean, and where the field realistically stands.
MDMA for PTSD: The Flagship That Stumbled
The MDMA-assisted therapy program for post-traumatic stress disorder was widely considered the most advanced psychedelic therapy in development. Sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) through its pharmaceutical arm Lykos Therapeutics, the program completed two Phase 3 trials.
The results were impressive. In the MAPP1 trial (Nature Medicine, 2021), 67% of the MDMA group no longer met PTSD criteria after three therapy sessions, compared to 32% on placebo. The MAPP2 confirmatory trial showed similar results.
Then came the FDA rejection. In August 2024, the FDA declined approval, citing functional unblinding (participants could tell whether they got MDMA or placebo), inadequate therapy standardization, and trial site misconduct allegations. The advisory committee had voted 9-2 against.
What this means: The data is promising for PTSD, but the path forward requires additional trials with better blinding and oversight. Realistic timeline for potential approval is 2027-2029 at the earliest.